5 Key Takeaways
-
1
CorneaGen launched Corneal Tissue Addition for Keratoplasty (CTAK) in June 2024, improving sight for keratoconus patients.
-
2
CTAK utilizes custom, gamma-irradiated, non-immunogenic corneal tissue inlays tailored to individual patient needs.
-
3
CorneaGen has performed over 1,000 CTAK procedures in the U.S. and expanded its reach internationally by September 2025.
-
4
The organization pioneered innovations in corneal transplantation, including the use of amphotericin B in storage media.
-
5
Bernie Iliakis, CorneaGen's CEO, emphasizes the importance of personal connections in corneal donation and transplantation.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.